case_images: PMC11108588_01
case_images: Evolution of serum free lambda light chain levels (mg/L) over time. The triangle corresponds to the initiation of elranatamab
case_images: chi_2024_6_2_116800_224728.jpg
case_images: PMC11108588_01_chi_2024_6_2_116800_224728.jpg
case_images: attachment-224728
case_images: From August 2022, she had a biological relapse with a gradual increase in lambda FLC (Figure 1). After one month of elranatamab treatment, a complete response was finally achieved, with FLC normalization (Figure 1).
case_images: 18-FDG-PETscan, showing left rib (a) and left iliac crest (b) plasmacytomas, invading soft tissues (white arrows)
case_images: chi_2024_6_2_116800_224729.jpg
case_images: PMC11108588_01_chi_2024_6_2_116800_224729.jpg
case_images: attachment-224729
case_images: A pelvic CT-scan showed that the iliac lesion had invaded soft tissues and measured five centimeters (Figure 2).
case_images: Pelvic CT-scan after two weeks of treatment, in bone window (a) and soft tissue window (b), showing a large lytic lesion of the left iliac crest invading soft tissues (white arrow)
case_images: chi_2024_6_2_116800_224730.jpg
case_images: PMC11108588_01_chi_2024_6_2_116800_224730.jpg
case_images: attachment-224730
case_images: The pelvic CT-scan revealed a discreet progression of the left iliac crest lesion, invading soft tissues and measuring 6 cm (Figure 3).
case_images: Thoracic CT-scan, showing SARS-CoV-2 pneumonia with severe involvement, affecting between 25 and 50% of the lung parenchyma, with associated atelectasis bands
case_images: chi_2024_6_2_116800_224731.jpg
case_images: PMC11108588_01_chi_2024_6_2_116800_224731.jpg
case_images: attachment-224731
case_images: SARS-CoV-2 pneumonia in October 2023, with extensive radiographic involvement (Figure 4), from which she recovered slowly. She remains in complete response at the latest follow-up, four months after treatment initiation.